Case Details
- Citation: [2016] SGHC 21
- Case Title: Hii Chii Kok v Ooi Peng Jin London Lucien and another
- Court: High Court of the Republic of Singapore
- Decision Date: 22 February 2016
- Case Number: Suit No 806 of 2012
- Judge: Chan Seng Onn J
- Coram: Chan Seng Onn J
- Plaintiff/Applicant: Hii Chii Kok
- Defendants/Respondents: (1) Ooi Peng Jin London Lucien (2) National Cancer Centre of Singapore Pte Ltd (“NCCS”)
- Parties (as described): Hii Chii Kok — Ooi Peng Jin London Lucien — National Cancer Centre of Singapore Pte Ltd
- Legal Areas: Tort — Negligence — Breach of duty; Tort — Negligence — Causation
- Key Legal Themes: Medical negligence in diagnosis and advice; informed consent vs Bolam–Bolitho; causation in clinical outcomes
- Procedural Note: The appeal to this decision in Civil Appeal No 33 of 2016 was dismissed by the Court of Appeal on 12 May 2017. See [2017] SGCA 38.
- Counsel for Plaintiff: Palaniappan Sundararaj and Lim Min (Straits Law Practice LLC)
- Counsel for First Defendant: Edwin Tong SC, Mak Wei Munn, Tham Hsu Hsien, Christine Tee and Hoh Jian (Allen & Gledhill LLP)
- Counsel for Second Defendant: Kuah Boon Theng, Felicia Chain, Gerald Soo and Karen Yong (Legal Clinic LLC)
- Judgment Length: 64 pages, 35,339 words
Summary
In Hii Chii Kok v Ooi Peng Jin London Lucien and another ([2016] SGHC 21), the High Court dismissed a claim in medical negligence arising from the plaintiff’s pancreatic surgery. The plaintiff, Dato’ Seri Hii Chii Kok, had been diagnosed clinically with pancreatic neuroendocrine tumours (“PNETs”) at two pancreatic sites (the pancreatic body and the uncinate process). He underwent a Whipple procedure and related pancreatic resection after being advised that surgery was an option, with an alternative of waiting for a period. Post-operative histopathology later revealed that he did not have PNETs; instead, he had a rare condition known as pancreatic polypeptide hyperplasia (“hyperplasia”).
The plaintiff sued the surgeon and the National Cancer Centre of Singapore, alleging negligence in diagnosis, advice, and post-operative management. The court held that the defendants were not negligent. Applying Singapore’s medical negligence framework—anchored in the Court of Appeal’s decision in Khoo James v Gunapathy—the judge applied the Bolam–Bolitho test to the questions of diagnosis and medical advice. Even if the court were to analyse the case through the lens of the more patient-centric informed consent approach associated with English law’s Montgomery, the court found that the defendants had still met the standard of reasonable care.
What Were the Facts of This Case?
The plaintiff was a Malaysian businessman with a law degree and experience as an English language journalist. His medical history included consultations in Malaysia for problems involving his lungs, thyroid, and prostate, and he had undergone surgery for hyperthyroidism in 2000. In 2003, nodules were discovered in his lungs. By 2010, the lung nodule had grown, and histopathology from a computed tomography-guided biopsy identified the lung nodule as a neuroendocrine tumour of low grade malignancy.
On 13 July 2010, the plaintiff consulted a medical oncologist in Malaysia, Dr Foo Yoke Ching, who diagnosed him with neuroendocrine carcinoma of the right lung. Dr Foo considered further investigation necessary and referred the plaintiff to the National Cancer Centre of Singapore for a Gallium scan. The referral reflected the plaintiff’s interest in obtaining surgery in Singapore, and the oncologist sought advice on the appropriate next steps.
On 19 July 2010, the plaintiff underwent a positron emission tomography scan using Gallium-68 DOTATATE (Gallium PET/CT). The scan showed marked tracer uptake in the pancreatic uncinate process and the pancreatic body, but no definite corresponding mass was seen on the imaging. The nuclear medicine physician, Dr Andrew Tan, informed the plaintiff that the increased uptake could suggest PNETs, but because no definite mass was visible, further imaging was recommended—specifically a contrast-enhanced CT or MRI.
The plaintiff proceeded promptly with an MRI scan on 20 July 2010. The MRI did not reveal a mass in the pancreatic lesions. The case was then scheduled for discussion by a multidisciplinary tumour board. The tumour board comprised specialists with relevant sub-specialty skills who would reach a consensus on diagnosis and treatment options. The court’s narrative emphasised that the diagnostic challenge was not merely technical; it involved distinguishing between PNETs and a rare, less serious condition (hyperplasia) that could produce similar imaging signals. The consensus of the experts at trial was that the most definitive method to differentiate the two conditions was post-operative histopathology, and that there was no reliable pre-operative diagnostic tool capable of making the distinction.
What Were the Key Legal Issues?
The first key issue was whether the defendants breached their duty of care in diagnosing the plaintiff’s condition and in advising him regarding treatment options. This required the court to determine the applicable standard for medical negligence in Singapore, particularly whether the Bolam–Bolitho test governed the assessment of negligence in diagnosis and advice, or whether the doctrine of informed consent should apply instead.
A second issue concerned causation and the relationship between any alleged breach and the plaintiff’s ultimate outcome. The plaintiff’s complaint was that, despite the desire for “aggressive treatment,” the post-operative findings showed hyperplasia rather than PNETs. The court therefore had to consider whether the defendants’ conduct fell below the required standard and, if so, whether that shortfall caused the plaintiff’s loss, including the consequences of undergoing surgery that ultimately was not for cancer.
Finally, the case raised an important doctrinal question about the evolution of medical negligence law: whether Singapore should follow the English approach in Montgomery v Lanarkshire Health Board, which moved away from Bolam–Bolitho toward a patient-centric informed consent framework for disclosure of material risks and reasonable alternatives. The judge noted that Singapore law, as a matter of binding precedent, required application of the Bolam–Bolitho test in medical advice cases, but he also considered whether the result would differ under an informed consent analysis.
How Did the Court Analyse the Issues?
The court began by setting out the governing legal framework for medical negligence in Singapore. The judge referred to Khoo James v Gunapathy, which established that the Bolam–Bolitho test applies in Singapore to questions of diagnosis and treatment. The judge then addressed the argument—raised in earlier High Court decisions—that informed consent principles should apply to advice about material risks and alternative treatments. He observed that the High Court is bound by Khoo James to apply the Bolam–Bolitho test to medical advice, and he aligned with that view.
At the same time, the judge engaged with the broader comparative development in English law. He explained that English law has moved away from Bolam–Bolitho toward informed consent following Montgomery, which emphasised a more patient-centric approach and required disclosure of material risks and reasonable alternatives based on what a reasonable person in the patient’s position would likely attach significance to. The judge noted that similar approaches exist in other jurisdictions. However, he concluded that, because Singapore’s position is governed by binding authority, the Bolam–Bolitho test remained the controlling standard for the issues before him.
Applying the Bolam–Bolitho test, the judge found that the defendants were not negligent in reaching the clinical diagnoses and were not negligent in the advice rendered to the plaintiff. The court’s reasoning turned on the nature of the diagnostic uncertainty. The defendants and the multidisciplinary tumour board had identified factors collectively suggesting that the plaintiff might have PNETs at two pancreatic sites. Crucially, they were also aware of the differential diagnosis—hyperplasia—and treated it as a possibility. The court accepted the expert consensus that no pre-operative investigative procedure could definitively differentiate PNETs from hyperplasia. In such circumstances, the standard of care did not require certainty; it required reasonable care in diagnosis and in communicating options.
The judge also addressed the plaintiff’s contention that the defendants should have ensured that he understood material risks and reasonable alternatives. He found that the plaintiff had been informed of both the clinical diagnosis and the differential diagnosis, and that the NCCS highlighted options including waiting for six months or proceeding with surgical resection of the pancreatic lesions. The plaintiff’s decision to proceed with “aggressive treatment” was therefore not presented as a product of ignorance or concealment. Even if the court were to apply the Montgomery informed consent approach, the judge held that the defendants would still not be negligent. This conclusion rested on the court’s finding that the plaintiff was made aware of the relevant diagnostic uncertainty and the available alternatives, including the option of waiting.
On post-operative management, the judge found no negligence by Prof Ooi. The court’s analysis reflected that the plaintiff’s complaint was, in substance, that the surgery did not yield the expected diagnosis. But the law of negligence does not impose liability merely because an outcome is different from what was clinically suspected. The question is whether the defendants met the standard of reasonable care in the circumstances, including the limits of pre-operative diagnostic tools.
What Was the Outcome?
The High Court dismissed the plaintiff’s claim. The court held that the defendants were not negligent in diagnosing the plaintiff’s condition, not negligent in advising him on treatment options, and not negligent in the post-operative management. The practical effect of the decision was that the plaintiff could not recover damages for the consequences of undergoing the Whipple surgery and pancreatic resection.
Although the plaintiff ultimately had hyperplasia rather than PNETs, the court treated that as an outcome consistent with the known diagnostic uncertainty. The dismissal therefore underscores that negligence in medical cases must be established by reference to the standard of care at the time of diagnosis and advice, not by hindsight from the histopathological result.
Why Does This Case Matter?
Hii Chii Kok is significant for practitioners because it clarifies how Singapore courts approach medical negligence claims involving diagnostic uncertainty and the disclosure of options. The decision reaffirms that, under current Singapore law, the Bolam–Bolitho test remains the controlling framework for assessing negligence in diagnosis and medical advice, consistent with Khoo James v Gunapathy. For litigators, this is important when drafting pleadings and framing expert evidence: the case demonstrates that courts will continue to evaluate whether a responsible body of medical opinion would support the diagnosis and advice, subject to the Bolitho requirement that such opinion must be logically defensible.
The case also matters because the judge engaged directly with the informed consent debate. While Singapore remains anchored to Bolam–Bolitho for medical advice due to binding precedent, the court’s willingness to consider what the result would be under an informed consent approach provides guidance. Practitioners can take from this that, even where informed consent arguments are raised, courts will scrutinise whether the patient was actually informed of diagnostic uncertainty and reasonable alternatives, and whether the disclosure met the standard of reasonable care.
From a practical standpoint, the decision highlights the evidential importance of multidisciplinary processes and documented discussions of options. The tumour board framework, the identification of differential diagnoses, and the communication of alternatives (including waiting) were central to the court’s conclusion. For healthcare institutions and clinicians, the case supports the view that transparent communication of uncertainty and options can be a strong defence against negligence claims, particularly where definitive pre-operative diagnosis is not available.
Legislation Referenced
- Statutes Referenced: None specified in the provided judgment extract.
Cases Cited
- Khoo James and another v Gunapathy d/o Muniandy and another appeal [2002] 1 SLR(R) 1024
- Bolam v Friern Hospital Management Committee [1957] 1 WLR 582
- Bolitho v City and Hackney Health Authority [1998] AC 232
- Surender Singh s/o Jagdish Singh and another (administrators of the estate of Narindar Kaur d/o Sarwan Singh, deceased) v Li Man Kay and others [2010] 1 SLR 428
- D’Conceicao Jeanie Doris (administratrix of the estate of Milakov Steven, deceased) v Tong Ming Chuan [2011] SGHC 193
- Tong Seok May Joanne v Yau Hok Man Gordon [2013] 2 SLR 18
- Montgomery v Lanarkshire Health Board (General Medical Council intervening) [2015] AC 1430
- Hii Chii Kok v Ooi Peng Jin London Lucien and another [2016] SGHC 21 (this case)
- Hii Chii Kok v Ooi Peng Jin London Lucien and another (appeal dismissed) [2017] SGCA 38
Source Documents
This article analyses [2016] SGHC 21 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.